

Global Blood Therapeutics, Inc.  
Form 8-K  
March 27, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event Reported): March 26, 2019**

**Global Blood Therapeutics, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction of**  
**Incorporation)**

**001-37539**  
**(Commission File Number)**

**27-4825712**  
**(I.R.S. Employer Identification**  
**Number)**

**171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080**

**(Address of Principal Executive Offices) (Zip Code)**

**(650) 741-7700**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 26, 2019, Charles Homcy, M.D., a member of the board of directors (the Board) of Global Blood Therapeutics, Inc. (the Company), notified the Company that he intends to resign from the Board, including the Research and Development Committee of the Board on which he currently serves, effective as of the Company's next annual meeting of stockholders, which is expected to be held on June 18, 2019 (the Annual Meeting), and accordingly, he will not stand for re-election at the Annual Meeting. Dr. Homcy's decision to resign was not the result of any disagreement with the Company on any matters relating to the Company's operations, policies or practices.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Global Blood Therapeutics, Inc.**

Date: March 26, 2019

By: /s/ Tricia Suvari  
Tricia Suvari  
Chief Legal Officer